Purple Biotech Ltd (PPBT)
| Market Cap | 6.13M +9.9% |
| Revenue (ttm) | n/a |
| Net Income | -24.49M |
| EPS | -0.01 |
| Shares Out | 2.17B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 146,092 |
| Open | 1.710 |
| Previous Close | 1.740 |
| Day's Range | 1.610 - 1.800 |
| 52-Week Range | 1.160 - 14.100 |
| Beta | -0.53 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 7, 2026 |
About PPBT
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin recept... [Read more]
Financial Performance
Financial StatementsNews
Why Is Purple Biotech (PPBT) Stock 42% Up Today?
Purple Biotech stock surged higher on Wednesday after the company announced a patent update.
Purple Biotech issued notice of allowance from USPTO
Purple Biotech (PPBT) announced that the U.S. Patent and Trademark Office, or USPTO, has issued a notice of allowance for a patent application covering tri-specific antibody constructs and methods of…
New U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific Antibodies
REHOVOT, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the “Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy pla...
Purple Biotech price target lowered to $17 from $30 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Purple Biotech (PPBT) to $17 from $30 and keeps a Buy rating on the shares. The firm cites the company’s “low” cash…
Purple Biotech presents new IM1240 data at EACR
Purple Biotech (PPBT) announced the presentation of new preclinical data from its CAPTN-3 program, IM1240, at the European Association for Cancer Research, or EACR, 2026 Annual Congress, being held Ju...
Purple Biotech files $200M mixed securities shelf
17:30 EDT Purple Biotech (PPBT) files $200M mixed securities shelf
Purple Biotech reports IM1240 demonstrates potent anti-tumor activity
Purple Biotech (PPBT) announced new preclinical data supporting the clinical potential of IM1240, the company’s lead CAPTN-3 tri-specific antibody. IM1240 is a conditionally activated, capped-CD3x5T4x...
Purple Biotech announces collaboration with Converge Bio
Purple Biotech (PPBT) announced a collaboration with Converge Bio to accelerate and enhance Purple Biotech’s next-generation tri-specific antibody platform leveraging advanced generative AI capabiliti...
Purple Biotech regains compliance with Nasdaq
Purple Biotech (PPBT) received confirmation from the Listing Qualifications Department of Nasdaq that the company had regained compliance with the minimum bid price requirement for continued listing o...
Purple Biotech price target lowered to $30 from $34 at H.C. Wainwright
H.C. Wainwright analyst Emily Bodnar lowered the firm’s price target on Purple Biotech (PPBT) to $30 from $34 and keeps a Buy rating on the shares. The company reported Q4
Purple Biotech CEO Gil Efron to step down in August
Purple Biotech (PPBT) announced that Gil Efron, CEO, will step down from his role as CEO effective August 2026. Efron will remain actively involved with the Company, transitioning to lead
Purple Biotech reports Q4 EPS ($19.85) vs. ($2.00) last year
“In 2025, we focused on the CAPTN-3 platform and the value it can generate for patients and shareholders, naming a second tri-specific antibody from the platform, IM1305, and strengthening the
Purple Biotech Announces CEO Transition
Gil Efron to Step Down as CEO in August 2026 for Health Considerations; Will Continue to Lead Corporate Development
Purple Biotech trading halted, news pending
19:50 EST Purple Biotech (PPBT) trading halted, news pending
Purple Biotech to implement ADS ratio change
Purple Biotech (PPBT) announced that it intends to change the ratio of american depositary shares to its ordinary shares from the current ADS ratio of one ADS representing 200 ordinary
Purple Biotech Announces Plan to Implement ADS Ratio Change
ADS Will Begin Trading Reflecting the Ratio Change on March 2, 2026 REHOVOT, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a cl...
Purple Biotech completes toxicology study of IM1240
Purple Biotech (PPBT) announced successful completion of a non-human primates toxicology study of IM1240, a tri-specific antibody from its CAPTN-3 platform that targets 5T4, a tumor-specific antigen e...
Purple Biotech’s antibody platform shows anti-tumor activity
Purple Biotech (PPBT) reported positive new preclinical data from its CAPTN-3 tri-specific antibody platform presented at the ESMO Immuno-Oncology Congress 2025. These new preclinical data demonstrate...
Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress
New data showcase the versatility and anti-tumor activity of the CAPTN-3 platform and its unique multi-arm design in treatment-resistant cancers REHOVOT, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) --...
Purple Biotech reports Q3 EPS (29c) vs. (39c) last year
“During the quarter, we secured the necessary funds to support the development of our CAPTN-3 technology platform through significant milestones. We plan to conduct non-GLP and GLP toxicology studies,...
Purple Biotech sees cash runway into 1H27
As of September 30, 2025, Purple Biotech (PPBT) had cash and cash equivalents and short-term deposits of $10.5 million. The Company’s cash runway is expected into the first half of
Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update
Initiated development of a second CAPTN-3 tri-specific antibody targeting TROP2 Manufacturing milestone achieved for IM1240, the first tri-specific 5T4-targeting antibody from the CAPTN-3 platform Cas...
Why Is Purple Biotech Stock (PPBT) Up 95% Today?
Purple Biotech stock gained on Wednesday after the company reached a production milestone.
Purple Biotech achieves manufacturing milestone for IM1240
Purple Biotech (PPBT) announced the achievement of a manufacturing milestone for IM1240, a tri-specific antibody from the CAPTN-3 platform, which targets the tumor-associated antigen 5T4, the activati...
Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform
Achieved commercially viable yield for IM1240, positioning the program competitively for future development Validates scalability of the CAPTN-3 tri-specific antibody platform IM1240, the first CAPTN-...